Crizotinib in MET-deregulated or ROS1-rearranged pretreated non–small cell lung cancer (METROS): A phase II, prospective, multicenter, two-arms trial

L. Landi, R. Chiari, M. Tiseo, F. D'Inca, C. Dazzi, A. Chella, A. Delmonte, L. Bonanno, D. Giannarelli, D.L. Cortinovis, F. de Marinis, G. Borra, A. Morabito, C. Gridelli, D. Galetta, F. Barbieri, F. Grossi, E. Capelletto, G. Minuti, F. MazzoniC. Verusio, E. Bria, G. Al, R. Bruno, A. Proietti, G. Fontanini, L. Crino, F. Cappuzzo

Research output: Contribution to journalArticle

Original languageItalian
Pages (from-to)7312-7319
Number of pages8
JournalClinical Cancer Research
Volume25
Issue number24
DOIs
Publication statusPublished - 2019

Cite this